Mesoblast (MESO) Short-term Investments (2015 - 2016)

Mesoblast (MESO) posted Short-term Investments of -$805000.0 for Q2 2016, little changed sequentially from -$805000.0 in Q1 2016.

Analysis

Mesoblast (MESO) Short-term Investments (2015 - 2016) Analysis & Trends

Mesoblast has reported Short-term Investments for 2 years, with the latest figure at -$805000.0 in Q2 2016.

Quarterly Short-term Investments changed N/A year-over-year to -$805000.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was -$805000.0 (changed N/A YoY) and the FY2016 annual result came in at -$805000.0, changed N/A from the prior year.
Short-term Investments steadied at -$805000.0 in Q2 2016 per MESO's latest filing, from -$805000.0 in the prior quarter.
Over five years, Short-term Investments peaked at -$805000.0 in Q4 2015 and troughed at -$805000.0 in Q4 2015.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Mesoblast	2.24 Bn	2.14 Bn	-

Historic Data

Download Data